Savara Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SVRA Nasdaq 2836 www.savarapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Savara Inc.

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - May 27th, 2026 2:05 pm
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - May 23rd, 2026 4:33 pm
Savara Inc. (SVRA) Reports Q1 Financial Results - May 22nd, 2026 12:43 pm
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 - May 20th, 2026 6:15 am
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - May 19th, 2026 12:15 pm
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - May 18th, 2026 12:55 pm
Savara Reports First Quarter Financial Results and Provides Business Update - May 12th, 2026 2:05 pm
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference - May 11th, 2026 2:05 pm
US High Growth Tech Stocks To Watch - Apr 27th, 2026 11:38 am
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim - Apr 26th, 2026 11:03 am
Savara Announces New Employment Inducement Grant - Apr 17th, 2026 2:05 pm
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Apr 15th, 2026 2:05 pm
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference - Apr 14th, 2026 6:05 am
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Apr 7th, 2026 6:05 am
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Mar 30th, 2026 6:05 am
High Growth Tech Stocks To Watch In The US March 2026 - Mar 26th, 2026 5:40 am
VR Adviser Adds Over 1 Million Savara Shares - Mar 15th, 2026 8:59 am
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - Mar 13th, 2026 6:05 am
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Mar 6th, 2026 2:05 pm
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed - Mar 6th, 2026 3:12 am